A study on drug coverage for cardiovascular conditions in Canada’s public pharmacare programs revealed significant inequities and deficiencies in access to medications. Only a third of Canadians are eligible for publicly funded drug plans, resulting in discordance with Canadian guidelines. Reimbursement decisions vary widely across provinces, with limited updates to formularies and no systematic process for new evidence. The study suggests a unified framework to improve infrastructure and ensure guideline-recommended care. Efforts to address these issues are crucial to provide consistent and evidence-based treatment for all Canadians, regardless of their place of residence. Other countries with decentralized healthcare systems may benefit from these findings.
Source link
Addressing inequities in cardiovascular drug access
